OctoPlus wins drug delivery evaluation contract for two compounds
OctoPlus, a European provider of drug formulation and clinical material manufacturing services, has signed a drug delivery technology evaluation contract for two compounds with an unnamed European biotech company. This is the eighth client for which OctoPlus will work on a controlled release formulation.
OctoPlus, a European provider of drug formulation and clinical material manufacturing services, has signed a drug delivery technology evaluation contract for two compounds with an unnamed European biotech company. This is the eighth client for which OctoPlus will work on a controlled release formulation.
If the evaluations are successful, the contract may progress to a full process development, manufacturing and licensing agreement.
The clinically most advanced product incorporating OctoPlus" technology is Biolex Therapeutics' lead product Locteron, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. Locteron is being manufactured for Biolex by OctoPlus and is currently in Phase IIb clinical studies.